In economic evaluations of colorectal cancer treatment, a study from Japan (35) assessed the cost-effectiveness of optimal treatment regimens for patients with KRAS wild-type metastatic colorectal cancer using FOLFIRI in combination with bevacizumab (Bmab), cetuximab (Cmab), or panitumumab (Pmab). The gene discussed is KRAS; the disease is metastatic colorectal cancer.